Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR

Hong,Young-Soo; Jang,Won-Jun; Chun,Kyung-Soo; Jeong,Chul-Ho

doi:10.3892/or.2014.3161

Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR

Authors:
- Young-Soo Hong
- Won-Jun Jang
- Kyung-Soo Chun
- Chul-Ho Jeong
View Affiliations

Affiliations: Korea Research Institute of Bioscience and Biotechnology (KRIBB), Yangcheong-ri, Ochang, Chungbuk 363-883, Republic of Korea, College of Pharmacy, Keimyung University, Daegu 704-701, Republic of Korea
Published online on: April 28, 2014 https://doi.org/10.3892/or.2014.3161
Pages: 2619-2624

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Heat shock protein 90 (Hsp90) is a molecular chaperone for numerous client proteins, many of which are crucial for the pathogenesis of non-small cell lung cancers (NSCLCs). To date, therapeutic approaches using epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib or erlotinib for the treatment of NSCLCs have been limited due to the emergence of acquired drug resistance mainly mediated by a secondary T790M mutation in EGFR. Considering this, Hsp90 inhibition seems promising as it leads to overall degradation of the oncogenic EGFR family proteins. In this regard, the present study provides the preclinical basis for a new Hsp90 inhibitor, WK88-1, for the treatment of NSCLCs harboring the T790M mutation in EGFR. Our data revealed that inhibition of Hsp90 by WK88-1 induced overall degradation of multiple oncogenic signaling molecules including EGFR, ErbB2 and ErbB3, leading to subsequent growth arrest and apoptosis in the gefitinib-resistant H1975 cell line. In addition, treatment with WK88-1 markedly inhibited proliferation, migration and invasion in H1975 cells. Moreover, an in vivo xenograft assay indicated that WK88-1 markedly suppressed tumor growth in the H1975 xenografts, highlighting the potential efficacy of WK88-1 for overcoming gefitinib resistance in NSCLCs harboring the T790M mutation in EGFR.

View Figures

View References

1	Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) (corrected). J Clin Oncol. 21:2237–2246. 2003.Erratum in: J Clin Oncol 22: 4863, 2004.
2	Lynch TJ, Adjei AA, Bunn PA Jr, et al: Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res. 12:4365s–4371s. 2006. View Article : Google Scholar : PubMed/NCBI
3	Perez-Soler R, Chachoua A, Hammond LA, et al: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 22:3238–3247. 2004. View Article : Google Scholar : PubMed/NCBI
4	Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
5	Laskin JJ and Sandler AB: Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat Rev. 30:1–17. 2004. View Article : Google Scholar : PubMed/NCBI
6	Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
7	Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
8	Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
9	Jackman D, Pao W, Riely GJ, et al: Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 28:357–360. 2010. View Article : Google Scholar : PubMed/NCBI
10	Pao W, Wang TY, Riely GJ, et al: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2:e172005. View Article : Google Scholar : PubMed/NCBI
11	Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007. View Article : Google Scholar : PubMed/NCBI
12	Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
13	Pao W, Miller VA, Politi KA, et al: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2:e732005. View Article : Google Scholar : PubMed/NCBI
14	Li D, Shimamura T, Ji H, et al: Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell. 12:81–93. 2007. View Article : Google Scholar : PubMed/NCBI
15	Zhou W, Ercan D, Chen L, et al: Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature. 462:1070–1074. 2009. View Article : Google Scholar : PubMed/NCBI
16	da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P and Marais R: Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 65:10686–10691. 2005.PubMed/NCBI
17	Shimamura T, Lowell AM, Engelman JA and Shapiro GI: Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res. 65:6401–6408. 2005. View Article : Google Scholar
18	Webb CP, Hose CD, Koochekpour S, et al: The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res. 60:342–349. 2000.PubMed/NCBI
19	Yang S, Qu S, Perez-Tores M, et al: Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. Cancer Res. 66:6990–6997. 2006. View Article : Google Scholar : PubMed/NCBI
20	Pratilas CA, Hanrahan AJ, Halilovic E, et al: Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res. 68:9375–9383. 2008. View Article : Google Scholar : PubMed/NCBI
21	Shimamura T, Li D, Ji H, et al: Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res. 68:5827–5838. 2008. View Article : Google Scholar : PubMed/NCBI
22	Sausville EA, Tomaszewski JE and Ivy P: Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets. 3:377–383. 2003. View Article : Google Scholar
23	Supko JG, Hickman RL, Grever MR and Malspeis L: Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol. 36:305–315. 1995. View Article : Google Scholar : PubMed/NCBI
24	Kim W, Lee D, Hong SS, et al: Rational biosynthetic engineering for optimization of geldanamycin analogues. Chembiochem. 10:1243–1251. 2009. View Article : Google Scholar : PubMed/NCBI
25	Kim W, Lee JS, Lee D, et al: Mutasynthesis of geldanamycin by the disruption of a gene producing starter unit: generation of structural diversity at the benzoquinone ring. Chembiochem. 8:1491–1494. 2007. View Article : Google Scholar : PubMed/NCBI
26	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar
27	Koga F, Kihara K and Neckers L: Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90. Anticancer Res. 29:797–807. 2009.PubMed/NCBI
28	Whitesell L and Lindquist SL: HSP90 and the chaperoning of cancer. Nat Rev Cancer. 5:761–772. 2005. View Article : Google Scholar : PubMed/NCBI
29	Jolly C and Morimoto RI: Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst. 92:1564–1572. 2000. View Article : Google Scholar : PubMed/NCBI
30	Workman P: Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol Med. 10:47–51. 2004. View Article : Google Scholar : PubMed/NCBI
31	Gallegos Ruiz MI, Floor K, Roepman P, et al: Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PloS One. 3:e00017222008.PubMed/NCBI
32	Engelman JA, Janne PA, Mermel C, et al: ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA. 102:3788–3793. 2005. View Article : Google Scholar : PubMed/NCBI
33	Shimamura T and Shapiro GI: Heat shock protein 90 inhibition in lung cancer. J Thorac Oncol. 3:S152–S159. 2008. View Article : Google Scholar : PubMed/NCBI